Opus Genetics (IRD) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Opus Genetics (NASDAQ: IRD):

• 11/15/2025 – Opus Genetics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/13/2025 – Opus Genetics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
• 11/7/2025 – Opus Genetics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
• 10/29/2025 – Opus Genetics is now covered by analysts at Wedbush. They set an “outperform” rating and a $8.00 price target on the stock.
• 10/16/2025 – Opus Genetics is now covered by analysts at Chardan Capital. They set a “buy” rating and a $9.00 price target on the stock.
• 10/8/2025 – Opus Genetics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Opus Genetics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.